Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.53 |
| ▸ | KDR | P35968 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417985 | 1.00 | EGFR (0.63) | EGFRERBB2KDR | |
| SCHEMBL1418675 | 0.91 | EGFR (0.76) | EGFRERBB2KDR | |
| SCHEMBL1418198 | 0.89 | EGFR (0.80) | EGFRERBB2KDR | |
| SCHEMBL1418116 | 0.88 | EGFR (0.75) | EGFRERBB2KDR | |
| SCHEMBL4224657 | 0.86 | EGFR (0.67) | EGFRERBB2KDR | |
| SCHEMBL1418619 | 0.85 | EGFR (0.57) | EGFRERBB2 | |
| SCHEMBL1418621 | 0.85 | EGFR (0.57) | EGFRERBB2 | |
| SCHEMBL1418430 | 0.85 | EGFR (0.69) | EGFRERBB2KDR | |
| SCHEMBL1418431 | 0.85 | EGFR (0.69) | EGFRERBB2KDR | |
| SCHEMBL6502203 | 0.85 | EGFR (0.60) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298746-A1 | 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-6972288-B1 | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-12-06 | — | — | US | disclosed |